Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Tyler, TX
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Abingdon, VA
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Abingdon, VA
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Richmond, VA
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Spokane, WA
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Tacoma, WA
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Washington,
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Revisiting Parental Survey for Screening for Obstructive Sleep Apnea in Patients Undergoing Polysomnography
Status: Enrolling
Updated:  1/3/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Revisiting Parental Survey for Screening for Obstructive Sleep Apnea in Patients Undergoing Polysomnography
Status: Enrolling
Updated: 1/3/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Potential Mechanism of Exercise Impairment in OSA
Pulmonary Vasoreactivity as a Potential Mechanism of Exercise Impairment in Obstructive Sleep Apnea
Status: Enrolling
Updated:  1/3/2018
University of California, San Diego
mi
from
San Diego, CA
Potential Mechanism of Exercise Impairment in OSA
Pulmonary Vasoreactivity as a Potential Mechanism of Exercise Impairment in Obstructive Sleep Apnea
Status: Enrolling
Updated: 1/3/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Determination of Upper Airway Collapsibility During Routine CPAP Titration
Determination of Upper Airway Collapsibility During Routine CPAP Titration
Status: Enrolling
Updated:  1/3/2018
University of California, San Diego
mi
from
San Diego, CA
Determination of Upper Airway Collapsibility During Routine CPAP Titration
Determination of Upper Airway Collapsibility During Routine CPAP Titration
Status: Enrolling
Updated: 1/3/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Diagnosing Respiratory Disease in Children Using Cough Sounds
Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds
Status: Enrolling
Updated:  1/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
Diagnosing Respiratory Disease in Children Using Cough Sounds
Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds
Status: Enrolling
Updated: 1/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Diagnosing Respiratory Disease in Children Using Cough Sounds
Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds
Status: Enrolling
Updated:  1/3/2018
Cleveland Clinic Children's
mi
from
Cleveland, OH
Diagnosing Respiratory Disease in Children Using Cough Sounds
Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds
Status: Enrolling
Updated: 1/3/2018
Cleveland Clinic Children's
mi
from
Cleveland, OH
Click here to add this to my saved trials
Diagnosing Respiratory Disease in Children Using Cough Sounds
Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds
Status: Enrolling
Updated:  1/3/2018
Texas Children's Hospital
mi
from
Houston, TX
Diagnosing Respiratory Disease in Children Using Cough Sounds
Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds
Status: Enrolling
Updated: 1/3/2018
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Ascorbic Acid (Vitamin C) Infusion in Human Sepsis
Ascorbic Acid (Vitamin C) Infusion in Human Sepsis
Status: Enrolling
Updated:  1/8/2018
Virginia Commonwealth University
mi
from
Richmond, VA
Ascorbic Acid (Vitamin C) Infusion in Human Sepsis
Ascorbic Acid (Vitamin C) Infusion in Human Sepsis
Status: Enrolling
Updated: 1/8/2018
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Impulsivity and Stimulant Administration
Impulsivity and Stimulant Administration
Status: Enrolling
Updated:  1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Impulsivity and Stimulant Administration
Impulsivity and Stimulant Administration
Status: Enrolling
Updated: 1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
Status: Enrolling
Updated:  1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
Status: Enrolling
Updated: 1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
PET Imaging in Cocaine Self Administration
Status: Enrolling
Updated:  1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
PET Imaging in Cocaine Self Administration
Status: Enrolling
Updated: 1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
Status: Enrolling
Updated:  1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
Status: Enrolling
Updated: 1/8/2018
Connecticut Mental Health Center
mi
from
New Haven, CT
Click here to add this to my saved trials
MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  1/8/2018
Northwell Health
mi
from
New Hyde Park, NY
MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 1/8/2018
Northwell Health
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
Status: Enrolling
Updated:  1/9/2018
Northwestern University
mi
from
Chicago, IL
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
Status: Enrolling
Updated: 1/9/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise
Status: Enrolling
Updated:  1/9/2018
Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
mi
from
Augusta, GA
Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise
Status: Enrolling
Updated: 1/9/2018
Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
mi
from
Augusta, GA
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Birmingham, AL
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Torrance, CA
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Rochester, MN
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Charleston, SC
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Greenville, SC
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Spartanburg, SC
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Richmond, VA
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Mar del Plata,
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Mar del Plata,
Click here to add this to my saved trials
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/10/2018
GSK Investigational Site
mi
from
Saint Charles, MO
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/10/2018
GSK Investigational Site
mi
from
Saint Charles, MO
Click here to add this to my saved trials
Use of Vasopressin Following the Fontan Operation
Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies
Status: Enrolling
Updated:  1/10/2018
Advocate Children's Hospital
mi
from
Oak Lawn, IL
Use of Vasopressin Following the Fontan Operation
Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies
Status: Enrolling
Updated: 1/10/2018
Advocate Children's Hospital
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
Status: Enrolling
Updated:  1/11/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
Status: Enrolling
Updated: 1/11/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Glendale, AZ
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Tempe, AZ
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Celebration, FL
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Celebration, FL
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Clearwater, FL
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
DeLand, FL
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Orlando, FL
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Lawrenceville, GA
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Charlotte, NC
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Gastonia, NC
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Gastonia, NC
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Medford, OR
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Portland, OR
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Easley, SC
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Easley, SC
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Greenville, SC
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Rock Hill, SC
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Spartanburg, SC
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated:  1/11/2018
Clinical Research Facility
mi
from
Boerne, TX
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Status: Enrolling
Updated: 1/11/2018
Clinical Research Facility
mi
from
Boerne, TX
Click here to add this to my saved trials